Abstract |
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient risk factors significantly influence CINV. The use of a combination of a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, dexamethasone, and a neurokinin-1 (NK-1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy. The first generation 5-HT3 receptor antagonists have been very effective in the control of chemotherapy induced emesis in the first 24 h postchemotherapy (acute emesis), but have not been as effective against delayed emesis (24-120 h postchemotherapy). Palonosetron, a second generation 5-HT3 receptor antagonist with a different half-life, a different binding capacity, and a different mechanism of action than the first generation 5-HT3 receptor antagonists appears to be the most effective agent in its class. Despite the control of emesis, nausea has not been well controlled by current agents. Olanzapine, a FDA approved antipsychotic that blocks multiple neurotransmitters: dopamine at D1, D2, D3, D4 brain receptors, serotonin at 5-HT2a, 5-HT2c, 5-HT3, 5-HT6 receptors, catecholamines at alpha1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors, has emerged in recent trials as an effective preventative agent for chemotherapy-induced emesis and nausea, as well as a very effective agent for the treatment of breakthrough emesis and nausea. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.
|
Authors | Rudolph M Navari |
Journal | Biochimica et biophysica acta
(Biochim Biophys Acta)
Vol. 1848
Issue 10 Pt B
Pg. 2738-46
(Oct 2015)
ISSN: 0006-3002 [Print] Netherlands |
PMID | 25838122
(Publication Type: Journal Article)
|
Copyright | Copyright © 2015 Elsevier B.V. All rights reserved. |
Chemical References |
- Antiemetics
- Antineoplastic Agents
- Isoquinolines
- Neurokinin-1 Receptor Antagonists
- Quinuclidines
- Receptors, Neurokinin-1
- Receptors, Serotonin, 5-HT3
- Serotonin 5-HT3 Receptor Antagonists
- Benzodiazepines
- Palonosetron
- Dexamethasone
- Olanzapine
|
Topics |
- Antiemetics
(pharmacokinetics, therapeutic use)
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Benzodiazepines
(pharmacokinetics, therapeutic use)
- Dexamethasone
(pharmacokinetics, therapeutic use)
- Half-Life
- Humans
- Isoquinolines
(pharmacokinetics, therapeutic use)
- Nausea
(chemically induced, metabolism, physiopathology, prevention & control)
- Neoplasms
(drug therapy, pathology)
- Neurokinin-1 Receptor Antagonists
(pharmacokinetics, therapeutic use)
- Olanzapine
- Palonosetron
- Quality of Life
- Quinuclidines
(pharmacokinetics, therapeutic use)
- Receptors, Neurokinin-1
(metabolism)
- Receptors, Serotonin, 5-HT3
(metabolism)
- Serotonin 5-HT3 Receptor Antagonists
(pharmacokinetics, therapeutic use)
- Vomiting
(chemically induced, metabolism, physiopathology, prevention & control)
|